- Research article
- Open Access
- Open Peer Review
Employment of an algorithm of care including chest physiotherapy results in reduced hospitalizations and stability of lung function in bronchiectasis
- Jordan Powner†1,
- Andrew Nesmith†1,
- Denay P. Kirkpatrick2,
- Jessica K. Nichols2,
- Brent Bermingham1 and
- George M. Solomon1, 3Email author
© The Author(s). 2019
- Received: 6 November 2018
- Accepted: 2 April 2019
- Published: 25 April 2019
There is a paucity of data on long term clinical effects of high frequency chest wall oscillation (HFCWO) in the Bronchiectasis population. Other therapies such as nebulized mucolytics and long term antibiotics have proven benefit on quality of life and exacerbation rate. In this study a treatment algorithm that included HFCWO as a component was initiated to see what the long term effects of the proposed algorithm were on lung function, antibiotic use, and exacerbation rates.
This was an observational comparative retrospective cohort study from database of patients with Bronchiectasis. Patients with > 2 exacerbations and significant symptom burden were enrolled to receive a treatment algorithm. The algorithm included: nebulized bronchodilators, mucolytics (hypertonic saline (3–7%) or n-acetylcysteine) inhaled daily or twice daily, thrice weekly macrolide therapy when appropriate, and high frequency chest wall oscillation (HFCWO) therapy (daily to twice daily per issued protocol) Outcomes from the cohort were analyzed for the subsequent twelve months after initiation to observe longitudinal lung function and clinical outcomes. Chart review was then done to obtain data the year prior to the start of the algorithm in this same cohort of patients.
Sixty-five patients received the Smart Vest® HFCWO system and were enrolled into the algorithm for treatment during the study period. Of the sixty-five patients, forty-three were eligible due to adequate 1-year baseline and follow up data at the time of the study initiation. The mean FEV1 remained stable at 1-year post enrollment (1.85 ± 0.60 L pre vs 1.89 ± 0.60 L post, p = NS) and the number of exacerbations requiring hospitalization was reduced (1.3 ± 1.0 pre vs. 0.46 ± 0.81 hospitalizations, post initiation, p < 0.0001). Antibiotic use overall was also reduced (2.5 ± 0.86 courses/year pre vs 2.1 ± 0.92 courses per year post initiation, p < 0.0001).
Standardized care for Bronchiectasis involving an algorithm for Mucociliary clearance that centers on initiation of HFCWO may help to reduce lung function decline, need for oral antibiotics, and reduced hospitalization rate.
- Chest physiotherapy
- High frequency chest wall oscillation
- Mucociliary clearance
- Treatment algorithm
- Lung function
Bronchiectasis is a disease state caused by a myriad of pathological processes. The phenotype of the disease remains largely unchanged with cough, sputum production, shortness of breath, and recurrent pulmonary infections. It is a disease that causes significant mortality and morbidity and is becoming more commonly diagnosed . Awareness and diagnosis of the condition is growing, but treatment options remain limited . Several treatment options that have been applied to Bronchiectasis caused by Cystic Fibrosis (CF) have been applied to Bronchiectasis with moderate success. Inhaled antibiotics such as tobramycin and colistin have been studied with improved outcomes on preventing exacerbations and treating bacterial infections [3, 4]. Long-term oral therapy with erythromycin was shown to decrease the number of exacerbations in a 12-month span, but also there remains concern about increased macrolide resistant in common pulmonary infections . Another macrolide, azithromycin, in a similar study has also shown to reduce exacerbations in a 12-month time period with chronic therapy, but can also induce macrolide resistance especially in nontuberculosis mycobacteria infections . A recent study concluded that prophylactic antibiotic therapy, either oral or inhaled, also decreased exacerbations in the frequent exacerbator phenotype; unfortunately it did not ameliorate exacerbations completely in this phenotype . Therefore, a greater understanding of therapies is needed to improve clinical outcomes for Bronchiectasis.
Another main stay of therapy in CF Bronchiectasis is augmenting and improving mucociliary clearance. Mucociliary clearance therapy involves uses of nebulized medication such as albuterol, hypertonic saline, and rhDNase as well as chest physiotherapy via HFCWO, oscillatory positive expiratory pressure(PEP) device, or manual chest percussion [8, 9]. Expiratory therapies such as active cycle breathing with huff coughing and autogenic drainage have shown to increase mucous clearance in Bronchiectasis and other pulmonary diseases . Inhaled medications rhDNase and hypertonic saline have had mixed success in Bronchiectasis . Contrary to its effect in CF, rhDNase caused a significant decrease in FEV1 and had a higher rate of exacerbation . Short term use (14 days) of rhDNase was also found to be ineffective on spirometry and quality of life . Hypertonic saline in CF has been shown to decrease exacerbations and improve lung function [13, 14]. In Bronchiectasis, hypertonic saline has been shown to increase mucous clearance, quality of life, and lung function in the short-term . Two different long term studies showed different effects of hypertonic saline on lung function and exacerbation rate in Bronchiectasis [16, 17]. One showed only improvement in quality of life and small airway dysfunction and another showed improvement in FEV1, FVC, and exacerbation rate. These studies provide a template for therapy for mucociliary clearance in Bronchiectasis while leaving the question of what more can be done?
Chest physiotherapy (CPT) with high frequency chest wall oscillation (HFCWO) has become an integral component of CF mucociliary clearance therapy in the US. In CF, vest physiotherapy has shown to provide therapeutic benefits in combination with the previous mentioned therapies . HFCWO-based CPT has had multiple studies looking at sputum production and lung function with approximately half of the studies showing favorable results of vest therapy over other therapies for airway mucociliary clearance . This makes HFCWO per vest therapy in CF a standard therapy, but there is minimal data to date for use in Bronchiectasis. One short term study in 2013 compared traditional chest physiotherapy to HFCWO using the Vest Airway Clearance System (Hill-Rom, Batesville, Indiana, USA) for 15 days and demonstrated a significant improvement in lung function with HFCWO . Therapy with HFCWO compared to traditional techniques had greater improvements in FEV1 and FVC, sputum production, quality of life, and decreased inflammatory markers in the sputum over the 15 days of the study. This study however was not designed to look at long term outcomes in lung function or antibiotic use.
Given the very limited short- and long-term data on HFCWO for treatment in Bronchiectasis, we initiated a single center study to look at the efficacy of a treatment algorithm which included HFCWO. The primary endpoint was to determine the clinical effectiveness of a treatment algorithm centered on novel early initiation of HFCWO as an airway clearance treatment along with adjunctive nebulized bronchodilators, nebulized mucolytics, and macrolide therapy for patients with Bronchiectasis.
The study protocol was approved by the IRB committee at the University of Alabama at Birmingham (UAB). Ethics approval and informed consent were waived by the IRB committee due to treatments being routine standard of care.
Patients were recruited for an observational comparative retrospective medical cohort study from the database of patients with Bronchiectasis in the UAB Adult Bronchiectasis Center. The diagnosis of Bronchiectasis was confirmed by high resolution computed tomography of the chest along with clinical symptoms of cough and sputum production. Patients were referred for advanced management of Bronchiectasis and were treated per the therapeutic algorithm if they reported greater than 2 exacerbations in the previous year and symptoms that warrant entry by the clinic staff. These symptoms included chronic cough, sputum production, or dyspnea. For study purposes an exacerbation was defined as patient reported or medical record evidence of: Increased cough/sputum production or change in chest imaging or change in lung function accompanied by treatment with antibiotics and/or corticosteroids. This was based off the consensus definition of a Bronchiectasis exacerbation as a deterioration in three or more of the.
following key symptoms for at least 48 h: cough; sputum volume and/or consistency; sputum purulence; breathlessness and/or exercise tolerance; fatigue and/or malaise; hemoptysis and a clinician determines that a change in bronchiectasis treatment is required . In this study a severe exacerbation was classified as the necessity for a course of intravenous antibiotics or hospitalization for treatment.
> 2 Exacerbations per Year?
1. Offer evaluation
Not included in Study
2. Start Nebulized Bronchodilator
3. Start Nebulized Mucolytic
4. Assess for Macrolide therapy
5. Initiate High Flow Chest Wall Oscillation
Patients were then followed in the outpatient clinical setting every 2–3 months for one year over the period of the study. The protocol involved clinic visits assessing patients clinically for exacerbations that required outpatient therapy with antibiotics and/or steroids, or hospitalization for treatment. Clinic visits also included spirometry to assess lung function as well as the need for above treatments. Pulmonary function (FVC, FEV1, and FEF25–75%) was measured at each visit. The patients selected to receive therapy per the algorithm, including a HFCWO vest, were then assessed to see if they received and initiated treatment with the device and if there was sufficient longitudinal lung function and clinical outcome data to be included in longitudinal review. The patients who met criteria were then subjected to further chart review and complete records were obtained for each patient. Subsequent review included assessing the number of hospitalizations, antibiotic usage, and baseline lung function during the year prior to initiation of the algorithm.
Baseline lung function was defined as the mean of all values of the parameters over that previous year (minimum of 2 discrete values). All function values were obtained using ATS standards . Percent predicted values were calculated for this mixed ethnicity population using the NHANESIII prediction rule.
Descriptive comparison statistics were used to compare the data obtained over the study period using the treatment algorithm to the data from the year prior to the initiation of the algorithm. Statistical analysis was done using Graphpad Prism 7.0 (GraphPad Software, La Jolla, CA). Given the non-parametric nature of the sample distribution, Wilcoxon and Mann-Whitney tests were used to compare group means pre- and post-treatment algorithm. Statistical significance was defined by a p-value less than 0.05.
Mean age, yr. (S.D.)
Percentage Female (%)
Percentage Caucasian (%)
Mean Baseline FEV1, L (S.D.)
Percentage of Patients Prescribed HTS
Percentage of Patients Prescribed NAC
Percentage of Patients Prescribed B.D.
Percentage of Patients Prescribed Azithromycin
Percentage of Patients Prescribed Inhalational Antibiotics
Percent of Patients with at least one positive culture for P.a.
In this cohort, 33% of the patients had severe exacerbations pre-algorithm therapy with a significant reduction in the number post-algorithm therapy. Even though greater than 45% of the patients did not require hospitalization pre-algorithm or post-algorithm, as seen in Fig. 2b, this was still is a significant reduction in hospitalizations.
Therapy for Bronchiectasis is understudied due to low awareness and under-diagnosis. Current therapies only demonstrate modest reduction in symptoms, improvement in quality, reduction in exacerbations and hospitalizations, preservation of lung, and reduction in mortality . Previous clinical reviews recommend airway clearance techniques, but only mention HFCWO showed benefit over PEP devices in one study [2, 24]. The British Thoracic Society does not include recommendations for HFCWO in use for Bronchiectasis . The latest guidelines for Bronchiectasis were published by the European Respiratory Society and recommend chest physiotherapy that may include HFCWO in appropriate patients . The endorsement for the use of HCWO is based on 1 short-term, small study which showed promise for the use of HFCWO in Bronchiectasis . The Thoracic Society of Australia and New Zealand also do not mention or recommend the use of HFCWO in their guidelines, but do recommend airway clearance techniques . Also, no studies involving HFCWO were included in the last comprehensive Cochrane review of treatments for bronchiectasis .
This is the first long-term study that involves a treatment algorithm for Bronchiectasis that involves standard therapies and standardized chest physiotherapy with HFCWO. These results demonstrate that a standardized treatment algorithm that includes HFCWO therapy can be a beneficial long-term treatment option for patients with Bronchiectasis to help improve symptom burden and quality of life. A significant reduction in hospitalizations was achieved in the study population being treated with the algorithm. The algorithm also decreased antibiotic use significantly and this may suggest an overall effective therapy in the prevention of all exacerbations and may show an even greater reduction in the frequent exacerbator phenotype. Unfortunately, the overall reduction in antibiotics may be modest in actuality and may not provide clinical significance.
Over the same year of therapy there was a stabilization of lung function. Neither the parameters of FEV1, FVC, FEF25–75% showed any significant decline while on therapy. None of the other therapies included in Table 1. except hypertonic saline in limited studies improves lung function long term [16, 17]. This effect may be a consequence of the treatment algorithm as a whole or the long term initiation of HFCWO as a unique component.
Exacerbations can cause decreases in lung function and prolonged treatment with antibiotics that may require hospitalizations. This treatment algorithm may help prevent courses of antibiotics, worsening lung function, and hospitalizations. In frequent exacerbators, only macrolide therapy has previously been shown to reduce the overall number of exacerbations [5, 6]. The results obtained in this trial represent that the algorithm successfully decreased exacerbations and hospitalizations. Overall exacerbation declines may then translate into improved cost savings, quality of life, and lung function over time.
The potential reduction of hospitalizations is particularly impactful given the association of hospitalizations with increased mortality and morbidity in Bronchiectasis . While it is a retrospective study the data shows promise for possible algorithmic care that includes HFCWO. The algorithm potentially decreases overall exacerbations, hospitalizations, and stabilizes lung function which could lead to cost-saving and improved quality of life in a debilitating condition. This was also shown in a patient group that was not sorted based on cause of Bronchiectasis but included patients with Bronchiectasis from any cause. Also, no patients were excluded due to known acute or chronic pulmonary infections or concurrent antibiotic use. The population in this study also included those considered to be the frequent exacerbator phenotype and did not exclude any patients based on any previous infections, reduced FEV1, radiographic severity, or overlapping COPD .
The weakness of any retrospective study includes biases that can be introduced during observation or analysis. There may have be effects on the outcomes due to the regular clinical visits by the patients and possible extra attention those enrolled may have received. In a single center there may be selection bias for patients and PI bias on the need to hospitalize patients for severe exacerbations. Exacerbations rates were also only measured by hospitalizations and antibiotic usage and mild exacerbations requiring increase in other therapies may have been missed. Compliance with the algorithm and its components could not be measured directly in between clinic appointments. Even though patients were provided chest vests and associated education, adherence to vest therapy and proper technique at home remains a question in this study. The sample size also does not allow analysis between distinct groups of Bronchiectasis or patients with different causes of Bronchiectasis or chronic infections. Pseudomonas infected patients were included in the cohort, meaning that this analysis also includes the frequent exacerbator phenotype. The study validates the need for a larger prospective study involving this therapeutic algorithm for Bronchiectasis.
Taken together, this retrospective cohort demonstrates feasibility of data collection in a cohort of complex bronchiectasis patients receiving a treatment algorithm that includes HFCWO. The data also demonstrates the ability of this algorithm to help stabilize key lung function parameters and suggest reduction of the rate of decline of lung function. At the same time, the treatment algorithm was associated with significant reductions in the rate of exacerbations and hospitalizations which would also help slow the decline of lung function over time by preventing exacerbations. Despite smart technologies in our EMR, the retrospective nature of this study limits the ability to accurately report the overall effect on the frequencies of all-grade exacerbations. Again, this study was limited by its single center status, possible PI bias on the need for antibiotics, and retrospective nature. Outcomes could have also been influenced by the investigators knowledge of the patients in the database when evaluating them in clinic and also the regular clinic visits by the patients. Further studies would need to be multicenter and have a larger sample size to be able to control and analyze the individual components of the algorithm. Smart technology could also be used to determine the level of use and adherence of the vest by the participant.
GMS acknowledges funding by by NIH (5KL2TR001419–02 to GMS) and CFF (Solomon18YO). Funding provided financial support for the statistical analysis of the collected data.
Availability of data and materials
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.
GMS, AN, and BB participated in the study design. GMS, JTP, DPK, and JKN contributed to clinical enrollment and supervision. MS and JP participated in data analysis/interpretation and critical review and revision of the manuscript. All authors approved the final draft prior to submission.
Ethics approval and consent to participate
Ethics approval and informed consent was waived by the University of Alabama at Birmingham IRB committee due to the study being standard of care. The IRB protocol number is IRB-150922010.
Consent for publication
The authors declare that they have no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- Aksamit TR, O'Donnell AE, Barker A, et al. Adult patients with bronchiectasis: a first look at the US bronchiectasis research registry. Chest. 2017;151(5):982–92.View ArticleGoogle Scholar
- McShane PJ, Naureckas ET, Tino G, et al. Non–cystic fibrosis bronchiectasis. Am J Respir Crit Care Med. 2013;188(6):647–56.View ArticleGoogle Scholar
- Scheinberg P, Shore E. A pilot study of the safety and efficacy of tobramycin solution for inhalation in patients with severe bronchiectasis. Chest. 2015;127(4):1420–6.Google Scholar
- Haworth CS, Foweraker JE, Wilkinson P, et al. Inhaled Colistin in patients with bronchiectasis and chronic Pseudomonas aeruginosa infection. Am J Respir Crit Care Med. 2014;189(8):975–82.View ArticleGoogle Scholar
- Serisier DJ, Martin ML, McGuckin MA, et al. Effect of long-term, low-dose erythromycin on pulmonary exacerbations among patients with non–cystic fibrosis bronchiectasis the BLESS randomized controlled trial. JAMA. 2013;309(12):1260–7.View ArticleGoogle Scholar
- Altenburg J, de Graaff CS, Stienstra Y, et al. Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non–cystic fibrosis bronchiectasis the BAT randomized controlled trial. JAMA. 2013;309(12):1251–9.View ArticleGoogle Scholar
- Chalmers JD, Aliberti S, Filonenko A, et al. Characterisation of the “frequent exacerbator phenotype” in bronchiectasis. Am J Respir Crit Care Med. 2018;197:1410–20.View ArticleGoogle Scholar
- Mogayzel, Jr PJ., Naureckas ET, Robinson KA, et al. Cystic fibrosis pulmonary guidelines chronic medications for maintenance of lung health. Am J Respir Crit Care Med 2013;187(7): 680–689.Google Scholar
- Flume PA, Robinson KA, O'Sullivan BP, Finder JD, et al. Cystic fibrosis pulmonary guidelines: airway clearance therapies. Respir Care. 2009;54(4):522–37.PubMedGoogle Scholar
- Fink JB. Forced expiratory technique, directed cough, and autogenic drainage. Respir Care. 2007;52(9):1210–23.PubMedGoogle Scholar
- O'Donnell AE, Barker IJS, et al. Treatment of idiopathic bronchiectasis with aerosolized recombinant human DNase I. Chest. 1997;113(5):1329–34.View ArticleGoogle Scholar
- Wills PJ, Wodehouse T, Corkery K, et al. Short-term recombinant human DNase in bronchiectasis. Effect on clinical state and in vitro sputum transportability. Am J Respir Crit Care Med. 1996;154(2 Pt 1):413–7.View ArticleGoogle Scholar
- Donaldson SH, Bennett WD, Zeman KL, et al. Mucus clearance and lung function in cystic fibrosis with hypertonic saline. N Engl J Med. 2006;354(3):241–25.View ArticleGoogle Scholar
- Elkins MR, Robinson M, Rose BR, et al. A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. N Engl J Med. 2006;354(3):229–40.View ArticleGoogle Scholar
- Kellett F, Redfern J, Niven RM. Evaluation of nebulised hypertonic saline (7%) as an adjunct to physiotherapy in patients with stable bronchiectasis. Respir Med. 2005;99(1):27–31.View ArticleGoogle Scholar
- Kellett F, Robert NM. Nebulised 7% hypertonic saline improves lung function and quality of life in bronchiectasis. Respir Med. 2011;105(12):1831–5.View ArticleGoogle Scholar
- Nicolson CHH, Stirling RG, Borg BM, et al. The long-term effect of inhaled hypertonic saline 6% in non-cystic fibrosis bronchiectasis. Respir Med. 2012;106(5):661–7.View ArticleGoogle Scholar
- McIlwaine MP, Alarie N, Davidson GF, et al. Long-term multicentre randomised controlled study of high frequency Chest Wall oscillation versus positive expiratory pressure mask in cystic fibrosis. Thorax. 2013;68:746–51.View ArticleGoogle Scholar
- Nicolini A, Cardini F, Landucci N, et al. Effectiveness of treatment with high-frequency Chest Wall oscillation in patients with bronchiectasis. BMC Pulmonary Medicine. 2013;13:21.View ArticleGoogle Scholar
- Hill AT, Haworth CS, Aliberti S, et al. Pulmonary exacerbation in adults with bronchiectasis: a consensus definition for clinical research. Eur Respir J. 2017;49(6):1700051.View ArticleGoogle Scholar
- Kempainen RR, Milla C, Dunitz J, Savik K, Hazelwood A, Williams C, et al. Comparison of settings used for high-frequency chest wall compression in cystic fibrosis. Respir Care. 2010;55(6):695701.Google Scholar
- Culver BH, Graham BL, Coates AL, et al. ATS Committee on proficiency standards for pulmonary function laboratories. Recommendations for a standardized pulmonary function report: an official American Thoracic Society technical statement. Am J Respir Crit Care Med. 2017;196:1463–72.View ArticleGoogle Scholar
- Chalmers JD, Restrepo MI. Bronchiectasis management the state of the union. Chest. 2017;152(6):1097–9.View ArticleGoogle Scholar
- Amalakuhan B, Maselli DJ, Martinez-Garcia MA. Update in bronchiectasis 2014. Am J Respir Crit Care Med. 2015;192:1155–61.View ArticleGoogle Scholar
- Pasteur MC, Bilton D, Hill AT, et al. British Thoracic Society guideline for non-CF bronchiectasis. Thorax. 2010;65:577.View ArticleGoogle Scholar
- Polverino E, Goeminne PC, McDonnell MJ, et al. European Respiratory Society guidelines for the management of adult bronchiectasis. Eur Respir J. 2017;50:1700629.View ArticleGoogle Scholar
- Chang AB, Bell SC, Torzillo PJ, et al. Chronic suppurative lung disease and bronchiectasis in children and adults in Australia and New Zealand Thoracic Society of Australia and New Zealand guidelines. Medical Journal of Australia. 201;202(3):130.Google Scholar
- Welsh EJ, Evans DJ, Fowler SJ, et al. Interventions for bronchiectasis: an overview of Cochrane systemic reviews. Cochrane Database of systemic Reviews. 2015;7.Google Scholar
- Chalmers JD, Goeminne P, Aliberti S, et al. The bronchiectasis severity index. An international derivation and validation study. Am J Respir Crit Care Med. 2014;189(5):576–85.View ArticleGoogle Scholar